Table 4.
Brensocatib PK Parameters After a Single Oral Dose (40 mg) in Fasted and Fed States (Part B, PK Population a )
| Japanese | White | |||
|---|---|---|---|---|
| Parameter | Fasted (n = 10) | Fed (n = 9) | Fasted (n = 10) | Fed (n = 10) |
| Cmax, ng/mL | 351.9 (29.6) | 297.4 (25.5) | 301.1 (41.1) | 302.2 (46.4) |
| Tmax, h | 1.27 (0.48‐3.5) | 3 (0.48‐6) | 1.25 (0.52‐8) | 2 (1‐6) |
| AUClast, ng ‧ h/mL | 5012 (31.9) | 4980 (33.5) | 5480 (34.1) | 5473 (30) |
| AUC∞, ng ‧ h/mL | 5470 (38.7) | 5493 (43.3) | 6679 (38.4) | 6496 (30.7) |
| t1/2, h | 19.28 (27.8) | 19.35 (38.3) | 28.87 (28) | 27.46 (19.7) |
| CL/F, L/h | 8.068 (29) | 8.301 (35.5) | 7.012 (45.5) | 6.868 (38.8) |
AUC∞, area under the plasma concentration–time curve from time 0 to infinity; AUClast, area under the plasma concentration–time curve from time 0 to the last time with quantifiable concentration; CL/F, apparent total drug clearance following oral administration; Cmax, maximum plasma concentration; CV, coefficient of variation; PK, pharmacokinetic; t1/2, terminal elimination half‐life; Tmax, time to maximum plasma concentration.
All values are arithmetic mean (CV%) except Tmax, which is median (range).
a
The PK population for part B included 20 participants (10 Japanese, 10 White) who received brensocatib and had evaluable PK data.